Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (BIO) Stock Competitors & Peer Comparison
See (BIO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIO | $254.86 | -2.75% | 7.2B | -3.45 | -$76.52 | N/A |
| ABT | $126.65 | +0.80% | 220.4B | 15.89 | $7.97 | +1.83% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $106.98 | +0.72% | 157.1B | 63.20 | $1.68 | N/A |
| SYK | $403.77 | +1.79% | 154.2B | 54.39 | $7.42 | +0.83% |
| MDT | $92.63 | +0.34% | 119.1B | 25.75 | $3.61 | +3.03% |
| EW | $80.01 | +5.55% | 46.9B | 33.47 | $2.39 | N/A |
| DXCM | $89.32 | +2.97% | 34.9B | 66.91 | $1.33 | N/A |
| PHG | $25.67 | -0.68% | 24.2B | 87.17 | $0.30 | +3.39% |
| STE | $229.09 | +0.81% | 22.7B | 37.44 | $6.16 | +0.99% |
Stock Comparison
BIO vs ABT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ABT has a market cap of 220.4B. Regarding current trading prices, BIO is priced at $254.86, while ABT trades at $126.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ABT's P/E ratio is 15.89. In terms of profitability, BIO's ROE is -0.32%, compared to ABT's ROE of +0.32%. Regarding short-term risk, BIO is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ABT's competition here
BIO vs BSX-PA Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BIO is priced at $254.86, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BIO's ROE is -0.32%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, BIO is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check BSX-PA's competition here
BIO vs BSX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, BSX has a market cap of 157.1B. Regarding current trading prices, BIO is priced at $254.86, while BSX trades at $106.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas BSX's P/E ratio is 63.20. In terms of profitability, BIO's ROE is -0.32%, compared to BSX's ROE of +0.12%. Regarding short-term risk, BIO is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check BSX's competition here
BIO vs SYK Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SYK has a market cap of 154.2B. Regarding current trading prices, BIO is priced at $254.86, while SYK trades at $403.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SYK's P/E ratio is 54.39. In terms of profitability, BIO's ROE is -0.32%, compared to SYK's ROE of +0.11%. Regarding short-term risk, BIO is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check SYK's competition here
BIO vs MDT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, MDT has a market cap of 119.1B. Regarding current trading prices, BIO is priced at $254.86, while MDT trades at $92.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas MDT's P/E ratio is 25.75. In terms of profitability, BIO's ROE is -0.32%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check MDT's competition here
BIO vs EW Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, EW has a market cap of 46.9B. Regarding current trading prices, BIO is priced at $254.86, while EW trades at $80.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas EW's P/E ratio is 33.47. In terms of profitability, BIO's ROE is -0.32%, compared to EW's ROE of +0.45%. Regarding short-term risk, BIO is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check EW's competition here
BIO vs DXCM Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, DXCM has a market cap of 34.9B. Regarding current trading prices, BIO is priced at $254.86, while DXCM trades at $89.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas DXCM's P/E ratio is 66.91. In terms of profitability, BIO's ROE is -0.32%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, BIO is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check DXCM's competition here
BIO vs PHG Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, PHG has a market cap of 24.2B. Regarding current trading prices, BIO is priced at $254.86, while PHG trades at $25.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas PHG's P/E ratio is 87.17. In terms of profitability, BIO's ROE is -0.32%, compared to PHG's ROE of +0.03%. Regarding short-term risk, BIO is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check PHG's competition here
BIO vs STE Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, STE has a market cap of 22.7B. Regarding current trading prices, BIO is priced at $254.86, while STE trades at $229.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas STE's P/E ratio is 37.44. In terms of profitability, BIO's ROE is -0.32%, compared to STE's ROE of +0.09%. Regarding short-term risk, BIO is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check STE's competition here
BIO vs PODD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, PODD has a market cap of 20.4B. Regarding current trading prices, BIO is priced at $254.86, while PODD trades at $293.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas PODD's P/E ratio is 52.22. In terms of profitability, BIO's ROE is -0.32%, compared to PODD's ROE of +0.35%. Regarding short-term risk, BIO is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check PODD's competition here
BIO vs ZBH Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ZBH has a market cap of 19.3B. Regarding current trading prices, BIO is priced at $254.86, while ZBH trades at $96.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ZBH's P/E ratio is 21.69. In terms of profitability, BIO's ROE is -0.32%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, BIO is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ZBH's competition here
BIO vs ABMD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BIO is priced at $254.86, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BIO's ROE is -0.32%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ABMD's competition here
BIO vs ALGN Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ALGN has a market cap of 14.9B. Regarding current trading prices, BIO is priced at $254.86, while ALGN trades at $205.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ALGN's P/E ratio is 37.44. In terms of profitability, BIO's ROE is -0.32%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, BIO is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ALGN's competition here
BIO vs SNN Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SNN has a market cap of 13.9B. Regarding current trading prices, BIO is priced at $254.86, while SNN trades at $31.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SNN's P/E ratio is 33.69. In terms of profitability, BIO's ROE is -0.32%, compared to SNN's ROE of +0.08%. Regarding short-term risk, BIO is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check SNN's competition here
BIO vs SWAV Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BIO is priced at $254.86, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BIO's ROE is -0.32%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, BIO is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check SWAV's competition here
BIO vs PEN Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, PEN has a market cap of 9B. Regarding current trading prices, BIO is priced at $254.86, while PEN trades at $234.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas PEN's P/E ratio is 218.00. In terms of profitability, BIO's ROE is -0.32%, compared to PEN's ROE of +0.04%. Regarding short-term risk, BIO is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check PEN's competition here
BIO vs GMED Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, GMED has a market cap of 7.4B. Regarding current trading prices, BIO is priced at $254.86, while GMED trades at $54.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas GMED's P/E ratio is 40.67. In terms of profitability, BIO's ROE is -0.32%, compared to GMED's ROE of +0.05%. Regarding short-term risk, BIO is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check GMED's competition here
BIO vs BIO-B Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, BIO-B has a market cap of 6.9B. Regarding current trading prices, BIO is priced at $254.86, while BIO-B trades at $247.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, BIO's ROE is -0.32%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, BIO is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check BIO-B's competition here
BIO vs BRKR Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, BRKR has a market cap of 6.4B. Regarding current trading prices, BIO is priced at $254.86, while BRKR trades at $42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas BRKR's P/E ratio is 80.65. In terms of profitability, BIO's ROE is -0.32%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, BIO is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check BRKR's competition here
BIO vs GKOS Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, GKOS has a market cap of 5.4B. Regarding current trading prices, BIO is priced at $254.86, while GKOS trades at $94.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas GKOS's P/E ratio is -41.55. In terms of profitability, BIO's ROE is -0.32%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, BIO is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check GKOS's competition here
BIO vs NARI Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BIO is priced at $254.86, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas NARI's P/E ratio is -59.24. In terms of profitability, BIO's ROE is -0.32%, compared to NARI's ROE of -0.18%. Regarding short-term risk, BIO is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check NARI's competition here
BIO vs IRTC Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, IRTC has a market cap of 4.3B. Regarding current trading prices, BIO is priced at $254.86, while IRTC trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas IRTC's P/E ratio is -42.73. In terms of profitability, BIO's ROE is -0.32%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, BIO is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check IRTC's competition here
BIO vs INSP Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, BIO is priced at $254.86, while INSP trades at $129.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas INSP's P/E ratio is 59.17. In terms of profitability, BIO's ROE is -0.32%, compared to INSP's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check INSP's competition here
BIO vs ITGR Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ITGR has a market cap of 3.8B. Regarding current trading prices, BIO is priced at $254.86, while ITGR trades at $108.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ITGR's P/E ratio is 46.55. In terms of profitability, BIO's ROE is -0.32%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, BIO is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ITGR's competition here
BIO vs TMDX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, TMDX has a market cap of 3.7B. Regarding current trading prices, BIO is priced at $254.86, while TMDX trades at $108.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas TMDX's P/E ratio is 76.14. In terms of profitability, BIO's ROE is -0.32%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, BIO is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check TMDX's competition here
BIO vs AXNX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BIO is priced at $254.86, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BIO's ROE is -0.32%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BIO is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check AXNX's competition here
BIO vs PRCT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, PRCT has a market cap of 3.1B. Regarding current trading prices, BIO is priced at $254.86, while PRCT trades at $56.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas PRCT's P/E ratio is -32.97. In terms of profitability, BIO's ROE is -0.32%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, BIO is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check PRCT's competition here
BIO vs LIVN Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, LIVN has a market cap of 2.4B. Regarding current trading prices, BIO is priced at $254.86, while LIVN trades at $43.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas LIVN's P/E ratio is -10.73. In terms of profitability, BIO's ROE is -0.32%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, BIO is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check LIVN's competition here
BIO vs NUVA Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BIO is priced at $254.86, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BIO's ROE is -0.32%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BIO is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check NUVA's competition here
BIO vs UFPT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, BIO is priced at $254.86, while UFPT trades at $239.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas UFPT's P/E ratio is 29.68. In terms of profitability, BIO's ROE is -0.32%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, BIO is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check UFPT's competition here
BIO vs ATEC Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, BIO is priced at $254.86, while ATEC trades at $11.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ATEC's P/E ratio is -9.50. In terms of profitability, BIO's ROE is -0.32%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, BIO is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ATEC's competition here
BIO vs CNMD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, BIO is priced at $254.86, while CNMD trades at $50.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas CNMD's P/E ratio is 13.37. In terms of profitability, BIO's ROE is -0.32%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, BIO is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check CNMD's competition here
BIO vs SSII Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SSII has a market cap of 1.4B. Regarding current trading prices, BIO is priced at $254.86, while SSII trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SSII's P/E ratio is -89.75. In terms of profitability, BIO's ROE is -0.32%, compared to SSII's ROE of -1.05%. Regarding short-term risk, BIO is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check SSII's competition here
BIO vs AORT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, BIO is priced at $254.86, while AORT trades at $31.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas AORT's P/E ratio is -61.59. In terms of profitability, BIO's ROE is -0.32%, compared to AORT's ROE of -0.07%. Regarding short-term risk, BIO is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check AORT's competition here
BIO vs HSKA Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BIO is priced at $254.86, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BIO's ROE is -0.32%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BIO is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check HSKA's competition here
BIO vs AHCO Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, BIO is priced at $254.86, while AHCO trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas AHCO's P/E ratio is 16.28. In terms of profitability, BIO's ROE is -0.32%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, BIO is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check AHCO's competition here
BIO vs ESTA Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, BIO is priced at $254.86, while ESTA trades at $43.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ESTA's P/E ratio is -13.59. In terms of profitability, BIO's ROE is -0.32%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, BIO is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ESTA's competition here
BIO vs SILK Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $254.86, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SILK's P/E ratio is -18.96. In terms of profitability, BIO's ROE is -0.32%, compared to SILK's ROE of -0.29%. Regarding short-term risk, BIO is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check SILK's competition here
BIO vs FNA Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $254.86, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas FNA's P/E ratio is -19.83. In terms of profitability, BIO's ROE is -0.32%, compared to FNA's ROE of -0.36%. Regarding short-term risk, BIO is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check FNA's competition here
BIO vs TNDM Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $254.86, while TNDM trades at $16.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas TNDM's P/E ratio is -5.70. In terms of profitability, BIO's ROE is -0.32%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, BIO is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check TNDM's competition here
BIO vs INMD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, INMD has a market cap of 1B. Regarding current trading prices, BIO is priced at $254.86, while INMD trades at $14.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas INMD's P/E ratio is 6.60. In terms of profitability, BIO's ROE is -0.32%, compared to INMD's ROE of +0.25%. Regarding short-term risk, BIO is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check INMD's competition here
BIO vs IART Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, IART has a market cap of 1B. Regarding current trading prices, BIO is priced at $254.86, while IART trades at $13.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas IART's P/E ratio is -34.51. In terms of profitability, BIO's ROE is -0.32%, compared to IART's ROE of -0.03%. Regarding short-term risk, BIO is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check IART's competition here
BIO vs CSII Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BIO is priced at $254.86, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas CSII's P/E ratio is -20.83. In terms of profitability, BIO's ROE is -0.32%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BIO is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check CSII's competition here
BIO vs SIBN Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SIBN has a market cap of 735.1M. Regarding current trading prices, BIO is priced at $254.86, while SIBN trades at $17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SIBN's P/E ratio is -27.38. In terms of profitability, BIO's ROE is -0.32%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, BIO is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check SIBN's competition here
BIO vs CRY Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, BIO is priced at $254.86, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas CRY's P/E ratio is 425.71. In terms of profitability, BIO's ROE is -0.32%, compared to CRY's ROE of -0.07%. Regarding short-term risk, BIO is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check CRY's competition here
BIO vs IRMD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, IRMD has a market cap of 716.1M. Regarding current trading prices, BIO is priced at $254.86, while IRMD trades at $56.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas IRMD's P/E ratio is 36.34. In terms of profitability, BIO's ROE is -0.32%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BIO is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check IRMD's competition here
BIO vs SMLR Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SMLR has a market cap of 695.1M. Regarding current trading prices, BIO is priced at $254.86, while SMLR trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SMLR's P/E ratio is -15.93. In terms of profitability, BIO's ROE is -0.32%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, BIO is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check SMLR's competition here
BIO vs AXGN Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, AXGN has a market cap of 608.7M. Regarding current trading prices, BIO is priced at $254.86, while AXGN trades at $13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas AXGN's P/E ratio is -83.53. In terms of profitability, BIO's ROE is -0.32%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, BIO is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check AXGN's competition here
BIO vs APEN Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BIO is priced at $254.86, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas APEN's P/E ratio is -9.43. In terms of profitability, BIO's ROE is -0.32%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BIO is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check APEN's competition here
BIO vs KIDS Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, KIDS has a market cap of 564.7M. Regarding current trading prices, BIO is priced at $254.86, while KIDS trades at $22.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas KIDS's P/E ratio is -12.95. In terms of profitability, BIO's ROE is -0.32%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, BIO is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check KIDS's competition here
BIO vs AVNS Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, AVNS has a market cap of 555.4M. Regarding current trading prices, BIO is priced at $254.86, while AVNS trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas AVNS's P/E ratio is -1.45. In terms of profitability, BIO's ROE is -0.32%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, BIO is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check AVNS's competition here
BIO vs CBLL Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, CBLL has a market cap of 546.8M. Regarding current trading prices, BIO is priced at $254.86, while CBLL trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas CBLL's P/E ratio is -12.10. In terms of profitability, BIO's ROE is -0.32%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, BIO is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check CBLL's competition here
BIO vs ZIMV Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ZIMV has a market cap of 527.9M. Regarding current trading prices, BIO is priced at $254.86, while ZIMV trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ZIMV's P/E ratio is -20.80. In terms of profitability, BIO's ROE is -0.32%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, BIO is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ZIMV's competition here
BIO vs SRDX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SRDX has a market cap of 514.8M. Regarding current trading prices, BIO is priced at $254.86, while SRDX trades at $37.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SRDX's P/E ratio is -25.71. In terms of profitability, BIO's ROE is -0.32%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, BIO is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check SRDX's competition here
BIO vs BFLY Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, BFLY has a market cap of 487.2M. Regarding current trading prices, BIO is priced at $254.86, while BFLY trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas BFLY's P/E ratio is -6.57. In terms of profitability, BIO's ROE is -0.32%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, BIO is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check BFLY's competition here
BIO vs BFLY-WT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, BFLY-WT has a market cap of 482.5M. Regarding current trading prices, BIO is priced at $254.86, while BFLY-WT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, BIO's ROE is -0.32%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, BIO is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check BFLY-WT's competition here
BIO vs CTKB Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, CTKB has a market cap of 467.4M. Regarding current trading prices, BIO is priced at $254.86, while CTKB trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas CTKB's P/E ratio is -41.00. In terms of profitability, BIO's ROE is -0.32%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, BIO is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check CTKB's competition here
BIO vs PACB Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, PACB has a market cap of 462.1M. Regarding current trading prices, BIO is priced at $254.86, while PACB trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas PACB's P/E ratio is -0.56. In terms of profitability, BIO's ROE is -0.32%, compared to PACB's ROE of -1.70%. Regarding short-term risk, BIO is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check PACB's competition here
BIO vs OFIX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, OFIX has a market cap of 441.6M. Regarding current trading prices, BIO is priced at $254.86, while OFIX trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas OFIX's P/E ratio is -3.05. In terms of profitability, BIO's ROE is -0.32%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, BIO is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check OFIX's competition here
BIO vs BVS Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, BVS has a market cap of 436M. Regarding current trading prices, BIO is priced at $254.86, while BVS trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas BVS's P/E ratio is -13.69. In terms of profitability, BIO's ROE is -0.32%, compared to BVS's ROE of -0.21%. Regarding short-term risk, BIO is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check BVS's competition here
BIO vs SENS Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SENS has a market cap of 418.1M. Regarding current trading prices, BIO is priced at $254.86, while SENS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SENS's P/E ratio is -5.04. In terms of profitability, BIO's ROE is -0.32%, compared to SENS's ROE of -7.46%. Regarding short-term risk, BIO is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check SENS's competition here
BIO vs PTHL Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, PTHL has a market cap of 415.4M. Regarding current trading prices, BIO is priced at $254.86, while PTHL trades at $29.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas PTHL's P/E ratio is -583.00. In terms of profitability, BIO's ROE is -0.32%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, BIO is more volatile compared to PTHL. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check PTHL's competition here
BIO vs TMCI Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, TMCI has a market cap of 358.6M. Regarding current trading prices, BIO is priced at $254.86, while TMCI trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas TMCI's P/E ratio is -6.71. In terms of profitability, BIO's ROE is -0.32%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, BIO is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check TMCI's competition here
BIO vs NNOX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, NNOX has a market cap of 331.6M. Regarding current trading prices, BIO is priced at $254.86, while NNOX trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas NNOX's P/E ratio is -5.71. In terms of profitability, BIO's ROE is -0.32%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, BIO is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check NNOX's competition here
BIO vs OM Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, OM has a market cap of 328.6M. Regarding current trading prices, BIO is priced at $254.86, while OM trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas OM's P/E ratio is -0.64. In terms of profitability, BIO's ROE is -0.32%, compared to OM's ROE of -1.45%. Regarding short-term risk, BIO is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check OM's competition here
BIO vs VREX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, VREX has a market cap of 325.8M. Regarding current trading prices, BIO is priced at $254.86, while VREX trades at $7.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas VREX's P/E ratio is -7.62. In terms of profitability, BIO's ROE is -0.32%, compared to VREX's ROE of -0.08%. Regarding short-term risk, BIO is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check VREX's competition here
BIO vs SNWV Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SNWV has a market cap of 324.4M. Regarding current trading prices, BIO is priced at $254.86, while SNWV trades at $36.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SNWV's P/E ratio is -6.08. In terms of profitability, BIO's ROE is -0.32%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, BIO is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check SNWV's competition here
BIO vs RXST Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, RXST has a market cap of 323.9M. Regarding current trading prices, BIO is priced at $254.86, while RXST trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas RXST's P/E ratio is -12.08. In terms of profitability, BIO's ROE is -0.32%, compared to RXST's ROE of -0.10%. Regarding short-term risk, BIO is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check RXST's competition here
BIO vs CLPT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, CLPT has a market cap of 317.4M. Regarding current trading prices, BIO is priced at $254.86, while CLPT trades at $11.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas CLPT's P/E ratio is -14.78. In terms of profitability, BIO's ROE is -0.32%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, BIO is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check CLPT's competition here
BIO vs CATX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, CATX has a market cap of 301M. Regarding current trading prices, BIO is priced at $254.86, while CATX trades at $4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas CATX's P/E ratio is -3.30. In terms of profitability, BIO's ROE is -0.32%, compared to CATX's ROE of -0.27%. Regarding short-term risk, BIO is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check CATX's competition here
BIO vs NPCE Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, NPCE has a market cap of 294.5M. Regarding current trading prices, BIO is priced at $254.86, while NPCE trades at $8.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas NPCE's P/E ratio is -10.95. In terms of profitability, BIO's ROE is -0.32%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, BIO is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check NPCE's competition here
BIO vs QTRX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, QTRX has a market cap of 272.9M. Regarding current trading prices, BIO is priced at $254.86, while QTRX trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas QTRX's P/E ratio is -4.72. In terms of profitability, BIO's ROE is -0.32%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, BIO is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check QTRX's competition here
BIO vs MASS Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, MASS has a market cap of 266.1M. Regarding current trading prices, BIO is priced at $254.86, while MASS trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas MASS's P/E ratio is -3.34. In terms of profitability, BIO's ROE is -0.32%, compared to MASS's ROE of -0.13%. Regarding short-term risk, BIO is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check MASS's competition here
BIO vs CERS Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, CERS has a market cap of 265.7M. Regarding current trading prices, BIO is priced at $254.86, while CERS trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas CERS's P/E ratio is -13.90. In terms of profitability, BIO's ROE is -0.32%, compared to CERS's ROE of -0.35%. Regarding short-term risk, BIO is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check CERS's competition here
BIO vs TCMD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, TCMD has a market cap of 245.3M. Regarding current trading prices, BIO is priced at $254.86, while TCMD trades at $10.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas TCMD's P/E ratio is 15.98. In terms of profitability, BIO's ROE is -0.32%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, BIO is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check TCMD's competition here
BIO vs VMD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, VMD has a market cap of 241.9M. Regarding current trading prices, BIO is priced at $254.86, while VMD trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas VMD's P/E ratio is 20.40. In terms of profitability, BIO's ROE is -0.32%, compared to VMD's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check VMD's competition here
BIO vs MXCT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, MXCT has a market cap of 239.2M. Regarding current trading prices, BIO is priced at $254.86, while MXCT trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas MXCT's P/E ratio is -5.62. In terms of profitability, BIO's ROE is -0.32%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, BIO is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check MXCT's competition here
BIO vs NVRO Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BIO is priced at $254.86, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BIO's ROE is -0.32%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BIO is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check NVRO's competition here
BIO vs BWAY Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, BWAY has a market cap of 221.7M. Regarding current trading prices, BIO is priced at $254.86, while BWAY trades at $11.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas BWAY's P/E ratio is 53.32. In terms of profitability, BIO's ROE is -0.32%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, BIO is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check BWAY's competition here
BIO vs CVRX Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, CVRX has a market cap of 217.4M. Regarding current trading prices, BIO is priced at $254.86, while CVRX trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas CVRX's P/E ratio is -3.90. In terms of profitability, BIO's ROE is -0.32%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, BIO is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check CVRX's competition here
BIO vs EYES Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, BIO is priced at $254.86, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas EYES's P/E ratio is N/A. In terms of profitability, BIO's ROE is -0.32%, compared to EYES's ROE of -0.26%. Regarding short-term risk, BIO is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check EYES's competition here
BIO vs MGRM Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, MGRM has a market cap of 205.4M. Regarding current trading prices, BIO is priced at $254.86, while MGRM trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas MGRM's P/E ratio is -11.36. In terms of profitability, BIO's ROE is -0.32%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, BIO is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check MGRM's competition here
BIO vs INGN Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, INGN has a market cap of 182.8M. Regarding current trading prices, BIO is priced at $254.86, while INGN trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas INGN's P/E ratio is -5.91. In terms of profitability, BIO's ROE is -0.32%, compared to INGN's ROE of -0.15%. Regarding short-term risk, BIO is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check INGN's competition here
BIO vs SGHT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, SGHT has a market cap of 180.4M. Regarding current trading prices, BIO is priced at $254.86, while SGHT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas SGHT's P/E ratio is -3.56. In terms of profitability, BIO's ROE is -0.32%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, BIO is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check SGHT's competition here
BIO vs RPID Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, RPID has a market cap of 178.8M. Regarding current trading prices, BIO is priced at $254.86, while RPID trades at $4.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas RPID's P/E ratio is -3.96. In terms of profitability, BIO's ROE is -0.32%, compared to RPID's ROE of -0.56%. Regarding short-term risk, BIO is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check RPID's competition here
BIO vs TLSI Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, TLSI has a market cap of 173.2M. Regarding current trading prices, BIO is priced at $254.86, while TLSI trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas TLSI's P/E ratio is -4.15. In terms of profitability, BIO's ROE is -0.32%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, BIO is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check TLSI's competition here
BIO vs PROF Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, PROF has a market cap of 170.7M. Regarding current trading prices, BIO is priced at $254.86, while PROF trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas PROF's P/E ratio is -4.69. In terms of profitability, BIO's ROE is -0.32%, compared to PROF's ROE of -0.70%. Regarding short-term risk, BIO is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check PROF's competition here
BIO vs ANIK Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ANIK has a market cap of 164.9M. Regarding current trading prices, BIO is priced at $254.86, while ANIK trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ANIK's P/E ratio is -15.33. In terms of profitability, BIO's ROE is -0.32%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, BIO is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ANIK's competition here
BIO vs ELMD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ELMD has a market cap of 158.1M. Regarding current trading prices, BIO is priced at $254.86, while ELMD trades at $18.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ELMD's P/E ratio is 23.86. In terms of profitability, BIO's ROE is -0.32%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, BIO is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ELMD's competition here
BIO vs LNSR Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, LNSR has a market cap of 155.4M. Regarding current trading prices, BIO is priced at $254.86, while LNSR trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas LNSR's P/E ratio is -2.69. In terms of profitability, BIO's ROE is -0.32%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, BIO is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check LNSR's competition here
BIO vs RCEL Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, RCEL has a market cap of 152.5M. Regarding current trading prices, BIO is priced at $254.86, while RCEL trades at $5.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas RCEL's P/E ratio is -2.63. In terms of profitability, BIO's ROE is -0.32%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, BIO is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check RCEL's competition here
BIO vs BSGM Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, BSGM has a market cap of 147.5M. Regarding current trading prices, BIO is priced at $254.86, while BSGM trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas BSGM's P/E ratio is -9.04. In terms of profitability, BIO's ROE is -0.32%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, BIO is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check BSGM's competition here
BIO vs OWLT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, OWLT has a market cap of 135M. Regarding current trading prices, BIO is priced at $254.86, while OWLT trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas OWLT's P/E ratio is -5.07. In terms of profitability, BIO's ROE is -0.32%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, BIO is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check OWLT's competition here
BIO vs LUNG Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, LUNG has a market cap of 134.5M. Regarding current trading prices, BIO is priced at $254.86, while LUNG trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas LUNG's P/E ratio is -2.32. In terms of profitability, BIO's ROE is -0.32%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, BIO is more volatile compared to LUNG. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check LUNG's competition here
BIO vs AVR Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, AVR has a market cap of 121.2M. Regarding current trading prices, BIO is priced at $254.86, while AVR trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas AVR's P/E ratio is -0.94. In terms of profitability, BIO's ROE is -0.32%, compared to AVR's ROE of -2.92%. Regarding short-term risk, BIO is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check AVR's competition here
BIO vs LUCD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, LUCD has a market cap of 119.6M. Regarding current trading prices, BIO is priced at $254.86, while LUCD trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas LUCD's P/E ratio is -0.94. In terms of profitability, BIO's ROE is -0.32%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, BIO is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check LUCD's competition here
BIO vs ICAD Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BIO is priced at $254.86, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BIO's ROE is -0.32%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, BIO is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check ICAD's competition here
BIO vs FONR Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, FONR has a market cap of 99.5M. Regarding current trading prices, BIO is priced at $254.86, while FONR trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas FONR's P/E ratio is 12.83. In terms of profitability, BIO's ROE is -0.32%, compared to FONR's ROE of +0.09%. Regarding short-term risk, BIO is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.Check FONR's competition here
BIO vs RBOT-WT Comparison July 2025
BIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 7.2B. In comparison, RBOT-WT has a market cap of 98.8M. Regarding current trading prices, BIO is priced at $254.86, while RBOT-WT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of -3.45, whereas RBOT-WT's P/E ratio is N/A. In terms of profitability, BIO's ROE is -0.32%, compared to RBOT-WT's ROE of -1.17%. Regarding short-term risk, BIO is less volatile compared to RBOT-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.Check RBOT-WT's competition here